The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).
Hongbin Chen
No relevant relationships to disclose
Manuel R. Modiano
No relevant relationships to disclose
Joel W. Neal
No relevant relationships to disclose
Julie R. Brahmer
No relevant relationships to disclose
James R. Rigas
No relevant relationships to disclose
Robert M. Jotte
Honoraria - Lilly
Natasha B. Leighl
No relevant relationships to disclose
Liming Liu
Employment or Leadership Position - Regeneron
Julie M. Lisano
Employment or Leadership Position - Regeneron
Alex A. Adjei
Honoraria - Daiichi Sankyo
Research Funding - Ardea Biosciences; Bayer; Pfizer; Syndax
Heather A. Wakelee
No relevant relationships to disclose